MedTrace Logo

IL-15 Enhanced NK Cell Therapy for Solid Tumors

NCT07621471 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-06-02

No results posted yet for this study

Summary

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Conditions

Interventions

DRUG

IL-15 enhanced engineered NK cells

Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.

BIOLOGICAL

IL-15 Enhanced Engineered NK Cells

Genetically engineered NK cells expressing IL-15

Sponsors & Collaborators

  • Genovn Therapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07621471 on ClinicalTrials.gov